SFDA To Speed Up Approval Process For Generics, New Drugs
This article was originally published in PharmAsia News
Executive Summary
China’s State FDA will delay processing approval applications for duplicated low-tech drugs and speed up the approval for new meds and generics depending on clinical needs, deputy commissioner Wu Zhen said.